Your Medical Mind_ How to Decide What Is Right for You - Jerome Groopman [123]
123 The study of Canadian women and how much control they want in decision making: Lesley F. Degner et al., “Information needs and decisional preferences in women with breast cancer,” JAMA 277 (1997), pp. 1485–1492. Also see differences in desire for control among patients with lung or colorectal cancer: Nancy L. Keating et al., “Cancer patients’ roles in treatment decisions: Do characteristics of the decision influence roles?” JCO 28 (2010), pp. 4364–4370.
124 The discovery and biological functions of the BRCA genes: Yoshio Miki et al., “A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1,” Science 266 (1994), pp. 66–71; Richard Wooster et al., “Identification of the breast cancer susceptibility gene BRCA2,” Nature 378 (1995), pp. 789–792; Ashok R. Venkitaraman, “Cancer susceptibility and the functions of BRCA1 and BRCA2,” Cell 108 (2002), pp. 171–182.
127 Choices related to being tested for BRCA mutation and which preventive measures are selected by women: Marc D. Schwartz et al., “Decision making and decision support for hereditary breast-ovarian cancer susceptibility,” Health Psychology (2005), pp. S78—S84; Thomas Goetz, The Decision Tree: Taking Control of Your Health in the New Era of Personalized Medicine (New York: Rodale Books, 2010); David K. Payne et al., “Women’s regrets after bilateral prophylactic mastectomy,” Annals of Surgical Oncology 7 (2000), pp. 150–154; Susan M. Domchek et al., “Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality,” JAMA 304 (2010), pp. 967–975; Laura Esserman, Virginia Kaklamani, “Lessons learned from genetic testing,” JAMA 304 (2010), pp. 1011–1012; Marc D. Schwartz et al., “Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients,” Cancer Epidemiology, Biomarkers & Prevention 14 (2005), pp. 1003–1007; Beth N. Peshkin et al., “Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing,” Cancer Epidemiology, Biomarkers & Prevention 11 (2002), pp. 1115–1118; Lisa J. Herrinton et al., “Efficacy of prophylactic mastectomy in women with unilateral breast cancer: A cancer research network project,” JCO 23 (2005), pp. 4275–4286; Jose G. Guillem et al., “ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes,” JCO 24 (2006), pp. 4642–4660; Marielle S. van Roosmalen et al., “Randomized trial of a shared decision-making intervention consisting of trade-offs and individualized treatment information for BRCA1/2 mutation carriers,” JCO 22 (2004), pp. 3293–3301; Lauren Scheuer et al., “Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers,” JCO 20 (2002), pp. 1260–1268.
127 The data we cite on different decisions about mastectomy and oophorectomy among BRCA positive women with or without cancer: Jeffrey R. Botkin et al., “Genetic testing for a BRCA1 mutation: Prophylactic surgery and screening behavior in women 2 years post testing,” American Journal of Medical Genetics 118A (2003), pp. 201–209; E. J. Meijers-Heijboer et al., “Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation,” Lancet 355 (2000), pp. 2015—2020; Marc D. Schwartz et al., “Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing,” JCO 21 (2003), pp. 4034–4041; Marc D. Schwartz et al., “Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients,” JCO 22 (2004), pp. 1823–1829; Caryn Lerman et al., “Prophylactic surgery decisions and surveillance